GPRC5D-Targeted CAR T Cells for Myeloma.

Sham MailankodySean M DevlinJonathan LandaKarthik NathClaudia DiamonteElizabeth J CarstensDouglas RussoRomany AuclairLisa FitzgeraldBriana CadzinXiuyan WangDevanjan SikderBrigitte SenechalVladimir P BermudezTerence J PurdonKinga HosszuDevin P McAvoyTasmin FarzanaElena MeadJessica A WilcoxBianca D SantomassoGunjan L ShahUrvi A ShahNeha KordeAlexander M LesokhinCarlyn R TanMalin HultcrantzHani HassounMikhail RoshalFiliz SenAhmet DoganOla LandgrenSergio A GiraltJae H ParkSaad Z UsmaniIsabelle RivièreRenier J BrentjensEric L Smith

Published in: The New England journal of medicine (2022)

The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol Myers Squibb; ClinicalTrials.gov number, NCT04555551.).

Keyphrases

cell therapy
multiple myeloma
cancer therapy
stem cells
mesenchymal stem cells
small molecule
drug delivery
bone marrow